AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors
Dr. Pfost noted, “AxoSim embodies the entrepreneur’s sweet spot--when market need, technological innovation, timing and team all align. The growing prevalence of neurological diseases places enormous burdens on patients, their families and society. Yet despite billions in investment, neurology R&D continues to disappoint. AxoSim’s transformational approach addresses a key contributor to these failures—the lack of relevant disease models—by providing functional human data from its microphysiological system (MPS) organoid technologies early in the process. AxoSim aims to become an industry leader in helping to deliver urgently needed new drugs and I welcome the opportunity to contribute to its success.”
- Dr. Pfost and Dr. Weiner have decades of experience in building successful biotechnology companies spanning therapeutics, diagnostics and life science tools and technologies.
- “Our recent acquisition of a third platform technology positions AxoSim for growth, and we are fortunate to have these two talented industry veterans assuming key leadership roles,” said Lowry Curley, PhD, co-founder and Chief Executive Officer of AxoSim.
- “Dale and Dave bring successful track records in building life sciences businesses, with broad and complementary skill sets.
- Dale’s work in life science tools and venture finance is highly relevant, as is Dave’s expertise in leading neurological drug discovery and clinical development.